Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. by Lowe, Emily L et al.
UCLA
UCLA Previously Published Works
Title
Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of 
colitis-induced cancer.
Permalink
https://escholarship.org/uc/item/91g4287g
Journal
PloS one, 5(9)
ISSN
1932-6203
Authors
Lowe, Emily L
Crother, Timothy R
Rabizadeh, Shervin
et al.
Publication Date
2010-09-27
DOI
10.1371/journal.pone.0013027
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Toll-Like Receptor 2 Signaling Protects Mice from Tumor
Development in a Mouse Model of Colitis-Induced
Cancer
Emily L. Lowe1, Timothy R. Crother1, Shervin Rabizadeh2, Bing Hu3, Hanlin Wang3, Shuang Chen1,
Kenichi Shimada1, Michelle H. Wong4, Kathrin S. Michelsen4*., Moshe Arditi1*.
1Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center and David Geffen School of Medicine at University of California Los Angeles, Los
Angeles, California, United States of America, 2Division of Pediatric Gastroenterology, Cedars-Sinai Medical Center and David Geffen School of Medicine at University of
California Los Angeles, Los Angeles, California, United States of America, 3Department of Pathology, Cedars-Sinai Medical Center and David Geffen School of Medicine at
University of California Los Angeles, Los Angeles, California, United States of America, 4 Inflammatory Bowel Disease Center & Immunobiology Research Institute, Burns and Allen
Research Institute, Cedars-Sinai Medical Center and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America
Abstract
Inflammatory bowel disease (IBD) is a disorder of chronic inflammation with increased susceptibility to colorectal cancer.
The etiology of IBD is unclear but thought to result from a dysregulated adaptive and innate immune response to microbial
products in a genetically susceptible host. Toll-like receptor (TLR) signaling induced by intestinal commensal bacteria plays a
crucial role in maintaining intestinal homeostasis, innate immunity and the enhancement of intestinal epithelial cell (IEC)
integrity. However, the role of TLR2 in the development of colorectal cancer has not been studied. We utilized the AOM-DSS
model for colitis-associated colorectal cancer (CAC) in wild type (WT) and TLR22/2 mice. Colons harvested from WT and
TLR22/2 mice were used for histopathology, immunohistochemistry, immunofluorescence and cytokine analysis. Mice
deficient in TLR2 developed significantly more and larger colorectal tumors than their WT controls. We provide evidence
that colonic epithelium of TLR22/2 mice have altered immune responses and dysregulated proliferation under steady-state
conditions and during colitis, which lead to inflammatory growth signals and predisposition to accelerated neoplastic
growth. At the earliest time-points assessed, TLR22/2 colons exhibited a significant increase in aberrant crypt foci (ACF),
resulting in tumors that developed earlier and grew larger. In addition, the intestinal microenvironment revealed
significantly higher levels of IL-6 and IL-17A concomitant with increased phospho-STAT3 within ACF. These observations
indicate that in colitis, TLR2 plays a protective role against the development of CAC.
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Introduction
Chronic inflammation and cancer are intertwined, especially in
the intestine, as seen in inflammatory bowel disease (IBD). IBD is
thought to result from a breakdown at the epithelial barrier,
followed by inappropriate responses to microbial products
resulting in chronic inflammation in a genetically susceptible host
[1]. IBD is associated with an increased risk for colorectal cancer
and it is now commonly believed that the chronic inflammation in
these patients leads to the neoplastic transformation of intestinal
epithelium [2]. Proper intestinal immunity relies on a balance
between immunosuppression and appropriately timed proinflam-
matory responses with protective inflammatory responses. Proin-
flammatory cytokines and chemokines that are produced during
chronic intestinal inflammation in response to commensal bacteria
create a microenvironment that enhances cell proliferation, cell
survival, and angiogenesis, thereby promoting tumorigenesis [3].
Intestinal epithelial cells (IEC) act as the first line of defense by
creating a barrier against microbes. The innate immune receptors
belonging to the family of Toll-like receptors (TLR) further help
IEC to distinguish friend from foe among the complicated milieu
of microbes. There is a growing body of evidence to support a
significant role for TLR signaling in the maintenance of intestinal
homeostasis [4,5,6,7,8,9]. Mice ablated of TLR2, TLR4, TLR9,
or their common adaptor molecule MyD88, were more acutely
susceptible to colitis induced by the chemical colitogen dextran
sodium sulfate (DSS), due in part to impaired protective responses
and reduced prostaglandin production [7,8,9,10,11]. Antibiotic
treatment worsened DSS-induced colitis in MyD882/2 mice and
prevented epithelial repair, indicating general TLR signaling is
required for proper IEC renewal. Indeed, treatment with TLR2
[8] and TLR9 [12] ligands during DSS administration ameliorat-
ed crypt damage and sped healing. TLR2-commensal signaling
preserves transepithelial resistance, promotes goblet cell mucin
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secretion, and maintains homeostasis within IEC [8,13,14,15].
Finally, because of its tendencies to skew towards TH2 responses
[16,17,18,19] and enhance regulatory T cell survival [20,21,22],
TLR2 signaling might play a major role in maintaining a
suppressive environment in the colon.
Various studies have implicated TLR signaling in intestinal
tumorigenesis. In multiple intestinal neoplasia (Min) mice, loss of
MyD88 signaling reduced tumor numbers and sizes suggesting
that MyD88 signaling contributes to tumor growth and progres-
sion [23]. In a different model, tumor incidence, multiplicity and
size were reduced after azoxymethane (AOM) and DSS treatment
when TLR4 was ablated in mice via reduction of TLR4
expression and signaling in IEC [24,25]. In addition, the colitis
and colitis-associated colorectal tumors (CAC) spontaneously
generated in IL102/2 mice can be ameliorated if mice are kept
in germ-free conditions [26] or concurrently ablated of TLR4
[27]. Taken together, these studies support that CAC development
depends on intestinal TLR recognition of commensal bacteria.
Despite the evident roles of TLR2 in IEC homeostasis and
enhancement of tolerance in the lamina propria microenviron-
ment [28,29], no study has elucidated the role that TLR2 might
play in transformation of intestinal epithelial cells leading to
intestinal tumors.
Here we demonstrate that TLR2-deficient mice develop more
and larger colonic tumors than WT control mice after AOM-DSS
treatment. Enhanced colonic tumor development is evidenced
early on by significantly increased numbers of aberrant crypt foci
(ACF) and increased IL-6, IL-17A, TNFa and phosphoSTAT3
expression in the intestinal microenvironment of TLR22/2 mice
as compared to WT mice. Our results demonstrate that TLR2 is
an important protective factor in intestinal epithelial homeostasis
and provide important insights into a previously unrecognized role
of TLR2 signaling in CAC.
Materials and Methods
Ethics Statement
All experiments were performed according to the guidelines and
approved protocols (IACUC #2838) of the Cedars-Sinai Medical
Center Institutional Animal Care and Use Committee and were
housed under specific pathogen free conditions.
Animals
Helicobacter-negative wild-type C57BL/6J and TLR22/2 (on
C57BL/6J background) mice were obtained from the Jackson
Laboratory (Bar Harbor, ME).
Induction of tumors (figure 1A)
Colitis-associated colorectal cancer (CAC) was induced as
previously described [30]. Briefly, 6–8 week old mice were
injected intraperitoneally (IP) with 12.5 mg/kg azoxymethane
(AOM; Sigma-Aldrich Chemical Co, St. Louis, MO). After 5 days,
mice received 2.5% dextran sulfate sodium (DSS; MP Biomed-
icals, Solon, OH, molecular weight 35,000–50,000 kDa) water for
5 days followed by 16 days of regular drinking water. Mice were
subjected to two DSS cycles, followed by a third cycle with 2%
DSS water administered for 4 days followed by regular water for
10 days. On day 61 post AOM injection mice were injected IP
with 100 mg/kg 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich
Chemical Co, St. Louis, MO) and sacrificed 2.5 h later. To
observe the earliest transformative steps in CAC, mice were
sacrificed 4 days after the completion of the first DSS cycle (14
days post AOM). The clinical course of disease was monitored by
measurement of body weight, observation of rectal bleeding,
diarrhea, and bloody stool during DSS treatment.
Histological Analysis for Colitis and Dysplasia
Entire colons were flushed with PBS and flash-frozen in the
swiss roll orientation. 7-mm sections were collected throughout the
depth of the colon using a cryostat and stained for hematoxylin
and eosin (H&E: Sigma-Aldrich). Histopathological alterations in
colitis and inflammation were scored by a Pathologist (HW)
blinded to the genotypes using the following scoring systems. Data
are presented in results section as ‘‘overall inflammation score’’,
which represents the sum of the scores given for ‘‘inflammation’’,
‘‘extent and severity of leukocyte infiltration’’ and ‘‘percent
involvement of the colon’’. The definition and scoring for these
subcriterias are as follows: Inflammation was defined and scored as: (0)
None to normal lymphoid aggregates; (1) Increased lymphoid
aggregates; (2) Cryptitis (neutrophils within crypt epithelium); (3)
Crypt abscess (neutrophils accumulating within crypt lumen,
sometimes with crypt rupture); (4) Ulceration (loss of mucosal
components and presence of granulation tissue). Extent of leukocyte
infiltration was scored as: (0) None; (1) infiltration confined to the
mucosa; (2) infiltration extending to the submucosa; (3) Transmu-
ral extension of inflitration. Severity of leukocyte infiltration was scored
based on number of infiltrating cells as: (1) Mild; (2) Moderate; (3)
Severe. Percent Involvement of colon was scored as: (0.25) if 1–25% of the
colon was involved; (0.50) if 26–50% of the colon was involved;
(0.75) if 51–75% of the colon was involved; (1.00) if 76–100% of
the colon was involved. Separately, we have also scored the ‘‘extent
necrosis’’ in the colon as follows: (1) = 25%, (2) = 50%, (3) = 75%,
(4) = 100%. Neoplasms were identified and also scored for severity
(adenoma or carcinoma in situ). Tumor burden in mice was
determined by the sum of the areas of all tumors per mouse.
BrdU and TUNEL Staining
All neoplasms observed by H&E were confirmed after BrdU
staining using BrdU In-Situ Detection Kit (BD Pharmingen, San
Diego, CA) according to manufacturer’s suggested protocol.
Apoptosis was detected using the In Situ Cell Death Detection
Fluorescein Kit (Roche, Indianapolis, IN), counterstained with
DAPI (Invitrogen, Carlsbad, CA) and quantified by fluorescence
intensity per focus field using ImagePro Plus (Media Cybernetics,
Silver Spring, MD). Proximal and distal regions of colon were
examined using greater than three focus fields per region in at least
four slides per animal.
Immunofluorescence
Frozen sections were fixed in 10% formalin. Slides stained for
nuclear antigens were further fixed in 100% methanol. Anti-
phospho-Stat3 and anti-ß-catenin (both from Cell Signaling
Technology, Danvers, MA) antibodies were incubated for 48 h
at 4uC followed by incubation with goat anti-rabbit-568 (Invitro-
gen, Carlsbad, CA). Biotinylated anti-nitrotyrosine (Cayman, Ann
Arbor, MI) was incubated overnight at 4uC followed by incubation
with streptavidin-594 (Invitrogen, Carlsbad, CA). All slides were
counterstained with DAPI (Invitrogen, Carlsbad, CA). Positive
cells were counted in greater than five focus fields in at least four
slides per animal and nuclear phospho-Stat3 intensity was
measured using ImagePro Plus.
Isolation and Treatment of Lamina Propria Mononuclear
Cells (LPMC) and Mesenteric Lymph Node Cells (MLN)
To obtain LP cells, entire colons were thoroughly flushed with
ice-cold PBS. One-mm pieces of colon were incubated in HBSS
TLR2 Colitis and Cancer
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supplemented with 1 mM DTT, 3 mM EDTA, 20 mM HEPES
with shaking at 37uC for 20 min. Colon pieces were washed with
HBSS followed by incubation in dissociation buffer (0.075 U/ml
Blendzyme 3, 1.5 U/ml Dispase II, 0.5 mg/ml DNase I [all Roche
Diagnostics, Mannheim, Germany], 20 mM HEPES, 1.3 mM
calcium chloride) with shaking at 37uC for 50 min. The digested
colons were vortexed briefly and further dissociated with increasing
gauge needles, passed through a 40 mm cell strainer and washed
with PBS. After centrifugation the cell pellet was resuspended in a
45% Percoll solution and laid over a 72% Percoll solution. Cells
located at the interphase were collected in a clean tube and washed
several times. MLN were crushed between glass slides and washed
with PBS. The cell suspension was passed through a 40 mm cell
strainer and washed with RPMI. Isolated lymphocytes were
resuspended in 10% FBS-high glucose RPMI supplemented with
L-glutamine (Cellgro; Mediatech Inc., Herndon, VA) and 1%
antibiotic/antimycotic (Sigma-Aldrich Chemical Co, St. Louis,
MO), and stimulated with 1 mg/ml anti-CD3 (eBioscience, San
Diego, CA) and 1 mg/ml anti-CD28 (eBioscience) for 72 h or with
1 mg/ml LPS (InvivoGen, San Diego, CA) for 6 h. Supernatants
were collected and stored at 280uC.
Preparation of Colon Homogenates
Colons were flushed thoroughly with ice-cold PBS. Colons were
then flash-frozen in liquid nitrogen. Washed and sterilized
Figure 1. TLR2-deficiency leads to increased development of colitis-associated colon cancer. (A) Schematic overview of the CAC model.
After initial AOM injection (12.5 mg/kg), DSS was given in the drinking water (boxed areas) followed by regular drinking water. Mice were sacrificed
on days 14 or 61 post AOM injection (Day 61: n = 19 WT, n= 21 TLR22/2 mice). (B) Percent weight change during AOM-DSS treatment. (C) Mouse
mortality during AOM-DSS treatments. (D) Number of colorectal tumors per mouse induced by AOM-DSS treatment at day 61. (E) Number of tumors
per mouse located in proximal or distal colons in WT or TLR22/2 mice. (F) Size distribution of colorectal tumors formed in WT or TLR22/2 mice. (G)
Tumor burden in AOM-DSS treated WT or TLR22/2 mice. All tests were performed using 95% confidence intervals. Data are expressed as means 6
SEM. * =p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0013027.g001
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zirconium oxide beads (0.5 mm diameter, Next Advance, Cam-
bridge, MA) were added in a volume equal to that of the tissue.
Colon tissues were then briefly mechanically homogenized using
the Bullet Blender (Next Advance, Cambridge, MA) at 4uC. An
isotonic lysis buffer (1 mM EDTA, 50 mM HEPES-NaOH,
pH 7.9, 250 mM NaCl, 20 mM ß-glycerophosphate, 1 mM
activated orthovanadate, 1% NP-40, 1 mM DTT) was then
added to the tissue and beads in a volume equal to that of the
tissue. This was further homogenized followed by rotation at 4uC
for 20 min. Homogenized tissues were centrifuged for 20 min at
4uC and 16,100 g and supernatants were stored at 280uC.
ELISAs
Supernatants, colon homogenates or serum were analyzed for
the presence of TNFa, IL-4, IFNg, IL-17A, IL-23p19 (all
eBioscience, San Diego, CA), IL-10, IL-6, TGFß, MIP-2 (all
R&D Systems, Minneapolis, MN), or KC, MCP-1 and RANTES
(all BD Biosciences, San Jose, CA), as per the manufacturer’s
suggested protocol.
Statistical analysis
Statistical analyses were performed using the software Graph-
Pad Prism 4. Statistical analysis of the survival curves was
performed using log-rank test. Statistical analyses of tumor sizes
were performed using the Mann-Whitney test for populations not
following Gaussian distributions. Comparisons of one-variable
data following Gaussian distributions were performed using a two-
tailed unpaired Student’s T-test. When an F-test indicated
variances differed significantly, Welch’s correction to the Student’s
T-test was employed. Comparisons of two variable data were
performed using two-way ANOVA with Bonferroni post test.
Comparisons of survival curve data were performed using the log-
rank (Mantel-Cox) test. All tests were performed using 95%
confidence intervals. Data are expressed as means 6 SEM.
* =p,0.05, ** = p,0.01, *** = p,0.001.
Results
TLR2-deficiency leads to increased development of
colitis-associated colon cancer
Previous studies have shown that TLR signaling and the
common adaptor molecule MyD88 are critically involved in
intestinal epithelial cell homeostasis and the development of
intestinal tumors [9,10,23,24], yet the role of TLR2 has not been
extensively studied. To examine the role of TLR2 during colitis-
associated tumorigenesis we used a well established model of CAC
[4,24,30,31,32]. WT and TLR22/2 mice received a single
injection of AOM followed by administration of three cycles of
DSS (Figure 1A). TLR22/2 mice had increased morbidity as
evidenced by increased weight loss during the course of treatment
(Figure 1B) and more rectal bleeding during DSS treatment as
compared to WT mice (data not shown). We also found increased
mortality in the TLR22/2 mice compared to wild type mice
(4.6% for WT and 25% for TLR22/2 mice, respectively, p,0.05),
with most deaths occurring shortly after the first course of DSS
(Fig 1C). Next, we examined the impact of TLR2-deficiency on
colitis-associated tumor development. TLR22/2 mice had a
higher tumor burden than WT mice. Histolopathological
examination revealed a significant increase in the numbers of
tumors in TLR22/2 compared to WT mice (Figure 1D). The
average tumor number per mouse was almost doubled in TLR2-
deficient mice compared to WT mice (6.1 vs. 3.5, p,0.05).
Because intestinal TLR2 is more strongly expressed in the
proximal colon [33], we hypothesized that mice lacking TLR2
would develop more CAC proximally. Indeed, the difference in
tumor development in TLR22/2 compared to WT mice was most
prominent in the proximal colon (Figure 1E). In addition to the
increase in tumor multiplicity, TLR2-deficiency also led to
significantly higher number of larger tumors (.1 mm2) (p,0.05)
(Figure 1F) and higher tumor burden (nearly double) in TLR22/2
mice compared to WT mice (p,0.05) (Figure 1G). These results
indicate that TLR2-deficiency not only enhances tumor promo-
tion but also increases tumor progression.
TLR2-deficient colons have more advanced dysplasia and
ß-catenin expression compared to WT colons
ß-catenin signaling plays an essential role in human intestinal
carcinogenesis [34] and mutations have been reported in AOM-
induced murine colonic tumors [30,31,35]. Indeed, strongly
positive cytoplasmic or nuclear ß-catenin staining was observed
in transformed tissue in WT and TLR22/2 mice (Figure 2B). WT
colorectal adenomas (Figure 2A, B, left 2 panels) displayed classic
tubular structures with distorted glands and moderate organiza-
tion. However, TLR22/2 colorectal neoplasms (Figure 2A, B,
right 2 panels) displayed more distorted glands with regions of
increased disorganization and cribriform structures indicative of a
higher grade dysplasia (i.e. carcinoma in situ). In fact, histological
analysis revealed almost twice the incidence of advanced
carcinoma in situ (0.3 vs 0.6 mean carcinoma in situ per mouse)
in TLR22/2mice as compared to WT, which trended towards
significance (p,0.055) (Figure S1).
TLR2-deficiency leads to increased early formation of
aberrant crypt foci and early intestinal tumorigenesis
Because TLR22/2 mice developed significantly larger colonic
tumors, we next examined WT and TLR2 deficient colons 14 days
into the AOM-DSS regimen for the earliest transformative events
during tumorigenesis. At this time point, TLR22/2 mice showed
significantly increased inflammation compared to WT mice
(overall inflammation score of 4 vs 6, p,0.001) (Figure 3A).
Colons from TLR22/2 mice contained moderate to severe
inflammation that extended transmurally while inflammation in
WT colons extended to similar depths but displayed only mild to
moderate infiltration of leukocytes (Figure 3D). The increased
inflammation found at this time point (day 14) in TLR22/2 mice
also correlated with the more severe body weight loss and
increased mortality during the first course of DSS in our long term
study (Fig 1B–C). WT mice further suffered more extensive
ulceration and necrosis than TLR22/2 mice (extent of necrosis in
colon 2.5 vs 1.3, p,0.01) (Figure 3B, D). Instead, TLR22/2 mice
showed signs of regeneration with mucin depletion, enlarged and
hyperchromatic nuclei, and increased nuclear to cytoplasmic ratio,
all indicative of aberrant crypt foci (ACF), which are known to be
pre-neoplastic [36] (Figure 3D, right panels). Furthermore, we
observed similar proliferation but reduced apoptosis in TLR22/2
ACF compared to WT ACF (Figure 3E, F), which may contribute
to survival of transformed cells. Indeed, quantitative analysis of
ACF revealed a significant increase in ACF in TLR22/2 mice
compared to WT mice in proximal (p,0.001) as well as distal
colons (p,0.01) (Figure 3C).
TLR2-deficiency have increased cell proliferation and
reduced apoptosis during early CAC development
Previous studies have demonstrated that recognition of com-
mensal bacteria via TLRs is required for intestinal epithelial
homeostasis, which is controlled by the balance of proliferation and
apoptosis in the crypts [10]. In order to compare intestinal
TLR2 Colitis and Cancer
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homeostasis between TLR22/2 mice and WT mice, we examined
epithelial cell proliferation by BrdU incorporation and apoptosis by
TUNEL staining for DNA fragmentation in colonic crypts.
Interestingly, prior to AOM-DSS we observed significantly reduced
numbers of BrdU+ cells (Figure 4A) with significantly increased
numbers of TUNEL+ cells (Figure 4B) per crypt in the proximal and
distal colons of TLR22/2mice compared to WT mice. In contrast,
after one round of DSS treatment (day 14), TLR22/2 colonic
crypts displayed increased BrdU+ cells (p,0.001) (Figure 4A, C)
and decreased TUNEL+ cells (p,0.001) (Figure 4B, D) compared
to WT mice, indicating dysregulated epithelial homeostasis in
TLR22/2 colons during inflammatory conditions. Furthermore,
although the BrdU+ cells were primarily localized to the stem cell
zone of WT crypts, proliferating cells were found extended into
the middle regions of the TLR22/2 crypts, in which epithelial cells
are normally differentiated and non-proliferating (Figure 4C).
Therefore, as mucosal integrity was compromised in colons
deficient of TLR2, the ability of the IEC to adhere to appropriate
survival and death signals was compromised, resulting instead in
dysregulated cell survival. To confirm that early intestinal
tumorigenesis in TLR22/2 mice is dependent on DSS-induced
inflammation we examinedWT and TLR22/2mice 14 days after a
single injection of AOM (no DSS treatment) as controls. We did not
observe any discernible ACF or increased inflammation in WT or
TLR2-deficient colons in these control experiments (Figure S2)
suggesting the importance of inflammation for the development of
tumors in the context of TLR2-deficiency.
TLR22/2 mice have increased IL-6 and STAT3 activation
during early intestinal tumorigenesis
In addition to increased cell proliferation and inflammation, we
detected significantly increased serum levels of IL-6 in TLR22/2
Figure 2. TLR2-deficient colons have more advanced dysplasia and ß-catenin expression compared to WT colons. Histopathology of
colons at day 61 of AOM-DSS treatment. (A) Hematoxylin and eosin (H&E) (left) or BrdU stained (right) serial sections of WT or TLR22/2 mice are
shown. Original magnification 20x (upper panels) and 100x (lower panels) are shown. (B) Immunofluorescent staining for ß-catenin. Original
magnification 100x (left panel) or 400x (right panel).
doi:10.1371/journal.pone.0013027.g002
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mice at early stages of tumorigenesis after initial AOM-DSS
treatment (day 14) compared to WT mice (p,0.05) (Figure 5A).
Importantly, IL-6 promotes tumor progression in inflammation-
associated tumor models through the activation of STAT3
[37,38]. We did not observe any significant differences in serum
concentrations of other pro-inflammatory cytokines or chemokines
(IL-12p40, IL-1beta, MCP-1, KC, and MIP-2) between WT and
TLR22/2 mice at day 14 of AOM-DSS treatment (data not
shown). We also detected increased IL-6 production in whole
colon homogenates from TLR22/2 mice at day 14 of AOM-DSS
treatment as compared to WT mice (p,0.01) (Figure 5B). Lamina
propria mononuclear cells (LPMC) isolated from TLR22/2 mice
treated with LPS also produced more IL-6 than WT LPMC
(p,0.05) (Figure 5C). Consistent with the increase in IL-6
production in TLR22/2 mice at early stages of tumorigenesis,
we observed significantly increased nuclear accumulation of
phosphorylated (activated) STAT3 (pSTAT3) in TLR22/2
epithelium compared to WT colons (Figure 5E). Quantification
of the intensity of nuclear pSTAT3 in ACF revealed an 8-fold
increase in pSTAT3 expression in TLR22/2 ACF compared to
WT ACF on day 14 (p,0.05) (Figure 5F). Additionally, while
nuclear pSTAT3 expression within TLR22/2 ACF was confined
to intact crypt epithelial cells (Figure 5E, right panel), nuclear
pSTAT3 in WT ACF appeared mostly in lamina propria or
abscessed crypts (Figure 5E, left panel). Quantitative analysis of
pSTAT3 at baseline did not reveal any differences in TLR22/2
vs. WT mice (Figure 5F).
TLR22/2 mice have an increased TH17 immune response
during CAC development
Recent studies have highlighted TH17 cells in the pathogenesis
of IBD [39] and colon tumorigenesis [40]. We examined the
expression of TH1, TH2 and TH17 cytokines in colons of WT and
TLR22/2 mice during early development of CAC. While we
observed decreased production of IFNg from colon homogenates
derived from TLR22/2 mice compared to WT mice on day 14
(Figure 6A), we observed significantly higher TNFa production in
TLR2-deficient colons compared to WT colons (p,0.05) (Fig 6H),
Figure 3. TLR2-deficiency leads to early formation of aberrant crypt foci. Scoring of inflammation, necrosis and ACF at day 14 of AOM-DSS
treatment (n = 5 WT and n= 5 TLR22/2). (A) Inflammatory scores of colons. (B) Extent of colonic necrosis. (C) Number of ACF per mouse located in
proximal or distal colons. (D) H&E stains of serial sections of colons. Original magnification 40x (upper panel) or 100x (lower panel). (E)
Immunohistochemical stains for BrdU. Original magnification 100x. (F) Immunofluorescent TUNEL staining. Original magnification 100x. All tests were
performed using 95% confidence intervals. Data are expressed as means 6 SEM. * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0013027.g003
TLR2 Colitis and Cancer
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e13027
a Th1 cytokine known to play a crucial role in CAC development
[32]. We did not observe any statistically significant differences in
IL-10 (Figure 6B) or IL-4 (Figure 6C) levels in the colonic
homogenates in these animals. In contrast, we observed a more
than 2-fold increase in IL-17A in TLR22/2 colon homogenates
compared to WT (p,0.05) (Figure 6D). Isolated LPMCs from
TLR22/2 mice also produced greater than 7-fold more IL-17A
compared to WT cells when restimulated with anti-CD3e and
anti-CD28 (p,0.001) (Figure 6E). We also observed significantly
increased production of TGF-b in TLR2-deficient colons
compared to WT colons (p,0.05) (Figure 6F). Increased
production of TGF-b..IL-6, and pStat3 in TLR2
2/2 mice com-
pared to WT further supports the involvement of TH17 cells.
IL-23p19 is a cytokine that has been implicated in the maintenance
of TH17 cells [41]. We observed that TLR2
2/2 colon homogenates
have significantly lower IL-23p19 levels at baseline compared to
WT colons (p,0.001) (Figure 6G). However, after day 14 of AOM-
DSS treatment, IL-23p19 production increased significantly
in TLR22/2 colons while decreasing in WT colons (p,0.001)
(Figure 6G), further supporting the interplay of TLR2 and TH17
cells in this model. Additionally, compared to WT colons at day 14
of AOM-DSS treatment, TLR22/2 colons displayed significantly
more colonic TNFa production (Figure 6H), known to play a crucial
role in CAC development [32]. Taken together, our data support
that TLR22/2 mice following AOM-DSS treatment are skewed
towards TH17 responses during early CAC development.
Figure 4. Increased cell proliferation and reduced apoptosis in TLR2-deficient colons during early CAC development. Assessment of
proliferation by BrdU staining and apoptosis by TUNEL staining in proximal and distal colons from mice either treated for 14 days with the AOM-DSS
regimen (Day 14) or untreated mice (Day 0) (n = 5), BrdU+ (A) and TUNEL+ (B) cells were counted in intact and well-oriented crypts. BrdU+ cells were
quantified from at least 20 crypts per region from 4 different slides per animal. (C) Day 14 representative immunohistochemical stains for BrdU in colonic
sections. Original magnification 100x. (D) Day 14 representative immunofluorescent stains for TUNEL stains in colonic sections. Original magnification
100x. All tests were performed using 95% confidence intervals. Data are expressed as means 6 SEM. * =p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0013027.g004
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Colonic tissue from TLR22/2 mice recruit inflammatory
cells that have reduced NO production and fail to mount
an adequate defense against tumor growth
To further understand the inflammatory milieu in the colons of
mice during early tumorigenesis in our experimental model, we
measured the expression of various chemokines in the colonic
tissue, including MCP-1 (CCL2), KC (CXCL1), MIP-2 (CXCL2)
and RANTES (CCL5), at day 14 of AOM-DSS treatment.
Colonic tissues from TLR22/2 mice produced significantly more
chemokines that play an important role in the recruitment of
neutrophils (KC and MIP-2) and macrophages (RANTES and
MCP-1) as compared to WT mice (p,0.01) (Figure 7A,C). These
chemokines resulted in increased colonic leukocyte infiltration and
overall inflammatory score (Figure 3A). These recruited cells can
have either pro- or anti-tumor function. In the presence of
Figure 5. TLR22/2mice have increased IL-6 and STAT3 activation during early intestinal tumorigenesis. Panels A–C: IL-6 production in WT
and TLR22/2 mice at day 14 of AOM-DSS treatment was measured by ELISA. (A) Serum levels of IL-6 (n= 8 WT, n= 9 TLR22/2). (B) IL-6 concentration in
colon homogenates was normalized to concentration of protein in the tissues (n= 3 WT, n=5 TLR22/2). (C) IL-6 secretion from isolated colonic lamina
propria cells treated with LPS (1 mg/ml) for 6 h (n= 3–5). (D) Immunofluorescent stains of phospho-Stat3 in colonic tissues of WT and TLR22/2 mice at
baseline. Original magnification 100x. (E) Immunofluorescent staining of phospho-Stat3 in colonic tissues of WT and TLR22/2 mice treated for 14 days
with the AOM-DSS regimen. Top panel original magnification 40x, bottom panel original magnification 400x. (F) Quantification of phospho-Stat3
intensity measured in ACF from greater than five focus fields in at least four slides per animal (n= 5 WT and n=5 TLR22/2). All tests were performed
using 95% confidence intervals. Data are expressed as means 6 SEM. * =p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0013027.g005
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Figure 6. TLR2-deficient mice develop increased TH17 responses during early CAC development. (A–D, F–H) Cytokines concentrations in
colon homogenates in WT and TLR22/2 mice at day 14 of AOM-DSS treatment were measured by ELISA. (A) IFN-g (n = 5–8). (B) IL-10 (n = 4). (C) IL-4
(n = 4–5). (D) IL-17A (n = 6). (E) IL-17A secretion from isolated chronic lamina propria cells treated with anti-CD3 (1 mg/ml) and anti-CD28 (1 mg/ml) for
72 h (n = 4). (F) TGF-ß (n = 4–10). (G) IL-23p19 (Day 0: n = 8–10; Day 14: n = 4= 10). (H) TNFa (n = 4–10). All tests were performed using 95% confidence
intervals. Data are expressed as means 6 SEM. * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0013027.g006
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increased TGFß they can have a pro-tumor effect and can
promote metastases [42,43]. Since we observed an increase in
colonic TGFß production in TLR22/2 mice together with an
increase granulocyte/myeloid cell infiltration, we suspected that
this recruited inflammatory cell population was conditioned
towards a pro-tumor phenotype rather than anti-tumor pheno-
type. One hallmark of anti-tumor cell infiltrates is increased nitric
oxide (NO) production by these cells, which enhances tumoricidal
activity, while pro-tumor infiltrates are poor producers of NO
[44,45,46]. To further investigate the phenotype of these inflam-
matory cells, we performed immunofluorescent staining to identify
nitrotyrosine positive cells, a good biomarker for NO production
[47,48,49], within lamina propria and near ACF of colons at day 0
and 14 of AOM-DSS treatment (Figure 7B, C). We observed very
few nitrotyrosine positive cells in colons of TLR22/2 and WT
mice at baseline (Figure 7C). However, by day 14, nitrotyrosine
positive cells had infiltrated both proximal (Figure 7B, top) and
distal (Figure 7B, bottom) colons, and we observed significantly less
nitrotyrosine positive cells in the TLR22/2 colons compared to
WT colons (p,0.001) (Figure 7B, C). The reduction in nitro-
tyrosine positive cells provides evidence that while TLR22/2 mice
display increased inflammatory cell infiltrates during early
tumorigenesis, these recruited immune cells fail to mount an
adequate defense against growing tumors.
Discussion
Innate immunity, especially Toll-like receptors, plays a
significant role in intestinal homeostasis. There is emerging data
on the importance of individual components that comprise innate
immunity and their relationship to IBD and cancer, however there
is a paucity of information on the role of TLR2. We provide a
Figure 7. Colonic tissue from TLR22/2 mice recruit inflammatory cells that have reduced NO production and fail to mount an
adequate defense against tumor growth in early CAC. (A) Chemokines concentrations quantified by ELISA in colon homogenates in WT and
TLR22/2mice at day 14 of AOM-DSS treatment were measured by ELISA. KC (n = 6 WT, n = 9 TLR22/2), MIP-2 (n = 6 WT, n = 9 TLR22/2), MCP-1 (n = 6
WT, n= 4 TLR22/2), RANTES (n = 4 WT, n = 10 TLR22/2). (B) Immunofluorescent staining for nitrotyrosine in proximal (top panels) and distal (bottom
panels) colon section of WT (left panels) and TLR22/2 (right panels) mice treated for 14 days with the AOM-DSS regimen. Original magnification 100x.
(C) Quantification of nitrotyrosine positive cells normalized by area (mm2) from greater than five focus fields in at least four slides per animal (n = 5 WT
and n= 5 TLR22/2).
doi:10.1371/journal.pone.0013027.g007
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previously unrecognized link between TLR2 and intestinal
tumorigenesis under chronic inflammatory conditions. In the
absence of TLR2, we observed greater tumor incidence, tumor
numbers and tumor sizes in a model of colitis-associated colon
cancer, providing evidence for the critical role TLR2 plays in
protection from CAC development and progression. In our model,
we observed increased inflammation as measured by increased
immune infiltration and production of proinflammatory cytokines
in TLR22/2 mice, which correlated with the increase in tumor
numbers and tumor sizes, in support of previously established links
between inflammation and colonic tumorigenesis [30]. We
establish a protective role for TLR2 in epithelial injury by (1)
maintenance of epithelial homeostasis, (2) maintenance of
regulatory mechanisms in colitis-associated inflammation, and (3)
development and progression of CAC.
Rakoff-Nahoum et al investigated the role of MyD88 signaling
during CAC formation and observed that MyD882/2 mice had
reduced tumor numbers [23]. However, that study did not use the
AOM-DSS model but used a different experimental model of
tumorgenesis, the ApcMin/+ model [23]. Additionally, MyD88,
which is also critical for proper repair of the intestinal tract, is
involved in many critical signaling pathways. Another study
conducted by Fukata et al investigated the role of TLR4 during
CAC development [24]. They also found reduced numbers of
tumors in TLR42/2 mice using the same AOM-DSS model we
used in the current study. This study suggests the critical role of
TLR4. Possibly TLR4 is the required proinflammatory signaling
pathway for CAC development while the data presented here
indicates TLR2 provides a suppressive environment in the
intestine. In our model, the increase in tumor multiplicity in
TLR2-deficient mice, particularly in the proximal colon where
there is the highest concentration of TLR2 and bacteria, indicates
that a pivotal source of inhibition during inflammation is
withdrawn when TLR2 is not present. This allows for dysregulated
proliferation and a subsequent increase in CAC tumor develop-
ment.
Recent studies have shown that intact NFkB signaling is
important for tumor development [30,50]. Further, several studies
have linked IL-6 production with colorectal cancer (reviewed in
[37]) and levels of serum IL-6 are increased in colorectal
carcinoma patients [51], which further correlated with tumor size
[52]. In this CAC model, we observed more IL-6 produced in the
serum, colon homogenates and lamina propria cells of TLR22/2
mice compared to WT mice. The proliferative and survival effects
of IL-6 on IEC are largely mediated by the transcription factor
Stat3 [38] as mice lacking Stat3 in colonic epithelium develop
fewer adenomas in spite of the fact that they have more severe
colitis following exposure to AOM-DSS [38]. In our study we have
observed that activated Stat3 was increased within the ACF
epithelium of TLR22/2 mice as compared to WT ACF
epithelium. IL-6, activated Stat3 and NFkB are intertwined in
the development of CAC. Not only can Stat3 increase NFkB
activity in tumors, but activation of Stat3 in immune cells in the
tumor is dependent on NFkB and IL-6 which is downstream from
NFkB. Interestingly, activated Stat3 inhibits lkB kinases (IKKs)
thus reducing NFkB associated TH1 immunity [53]. We observed
that mice deficient in TLR2 produced significantly less IFNg and
more TGFß, which coupled with the increase in IL-6 production,
led us to a TH17 skew. Indeed, IL-17 is a downstream target of IL-
6-induced Stat3 signaling [38,54,55,56]. The TH17 skewing that
we have observed in TLR2-deficient mice in the context of colitis-
induction in this study is consistent with recent findings linking IL-
17 and IL-23 variants with increased susceptibility to IBD [57,58].
Several animal models of colitis-induced colorectal cancer have
already linked IL-17 production with increased tumorigenesis
[40,59] and epithelial protection in the face of colitis [60].
Additionally, Chae et al recently showed that in the Apc(Min/+)
mouse model, IL-17A2/2 mice had drastically reduced intestinal
tumor numbers [61]. Hence, activation of Stat3 within the ACF
epithelium of TLR22/2 mice appears to promote a rise in NFkB
driven pro-cancer TH17 inflammatory pathway while suppressing
TH1 immunity.
We observed an increase in inflammatory infiltrates in TLR22/2
colons, consistent with prior studies that used DSS alone and found
that TLR2 deficiency may lead to exacerbation of intestinal
inflammation (10) and that TLR2 controls and protects mucosal
inflammation by regulating tight-junction (TJ) associated barrier
integrity [8]. However, as in the AOM/DSS model, we observed a
decrease in crypt damage in TLR2 deficient colons as compared to
WT colons. Further, consistent with the increase in anti-apoptotic
ACFs detected in TLR2-deficient, TLR22/2 crypts showed less
cryptitis and ulceration and displayed more signs of regeneration.
Conversely, WT colons exhibited more crypt atrophy and regions of
ulceration. Thus, in TLR2-deficient mice, tumor inducing circum-
stances, such as AOM/DSS, may suppress crypt damage and
promote proliferation by cytokines such as TGF-ß.
A recent study by Boulard et al [62] investigated the role of
TLR-2 in IBD where they used both a T-cell transfer model, and a
H. hepaticus model, to investigate the innate and adaptive responses
during the induction of chronic colonic inflammation. They found
that TLR2 played little to no role in the induction of either innate
or adaptive responses during the development of the inflamma-
tion. The authors concluded that the role of TLR-2 in IBD might
differ depending on the model and previous reports indicated a
requirement for TLR2 during acute intestinal inflammation
models such as DSS used here in this study [8,10]. Whether
there is any difference in the involvement of TLR2 in acute versus
chronic models of intestinal inflammation and CAC development
is unknown at this time.
The role of TLR2 in colitis-associated colorectal cancer
development is not well understood. Our study reveals a protective
role for TLR2 in this process. In this study we show in vivo evidence
that TLR2 signaling during colonic inflammation is essential in
regulating proliferation and apoptosis. Based on our observations
that TLR2-deficient mice exhibit unregulated proliferative growth
and ignorance of apoptotic signals during colitis, we describe a
new and critical role for TLR2-induced protection from epithelial
transformation. In the genetically susceptible host, IBD results
from a breakdown at the epithelial barrier, followed by
inappropriate responses to microbial products. TLR2-commensal
signaling provides enhanced epithelial barrier protection and pro-
survival signals to intestinal epithelial cells especially in the context
of inflammation by playing a critical role in promoting regulatory
immune responses and preventing pro-tumor inflammatory
skewing, thereby providing a protective role in the development
and progression of colitis-associated colorectal cancer. These
findings have broad implications towards the pathogenesis as well
as treatment of colitis-associated colorectal cancer in patients with
IBD.
Future studies similar to those that reported the essential role of
epithelial expression of TLR4 impacting expression of proin-
flammatory mediators within the lamina propria [25] utilizing
bone marrow chimeras will help dissect the importance of TLR2
in each compartment of intestinal immunity. Also, since
supplementation with TLR2 ligands during DSS-induced colitis
is shown to promote transepithelial resistance and thereby protect
from colitis [8], treatment with TLR2 ligands during the full
course of AOM-DSS could result in a reduction of tumor
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development. These observations could lead to new exciting
prophylactic and treatment approaches for colitis-associated
colorectal cancer.
Supporting Information
Figure S1 TLR2-deficient mice develop more progressive
colorectal tumors. Numbers of carcinoma in situ per mouse
induced by AOM-DSS treatment at day 61 (n= 19 for WT and
n=21 for TLR2-/- mice). The data shown are means 6 SEM.
Welch’s T-test, p = 0.19.
Found at: doi:10.1371/journal.pone.0013027.s001 (0.27 MB
TIF)
Figure S2 Treatment with AOM alone does not induce early
ACF. Representative H&E stains of proximal (A–B) and distal (C–
D) colons from WT and TLR22/2 mice 14 days after injection
of AOM without DSS treatment (n = 5 for WT and TLR22/2,
respectively). (A) Original magnification 20 x. (B) Original
magnification 100 x. (C) Original magnification 40 x. (D) Original
magnification 400 x.
Found at: doi:10.1371/journal.pone.0013027.s002 (6.70 MB
TIF)
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